REED'S, INC. - Common Stock, par value $0.0001 per share (REED)

CUSIP: 758338404

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
3
Total 13F value
$4
Holder snapshot 3 signals
Share change
0
SEC-reported price per share
$1.33
Number of holders
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
11,893,587

Security key

758338404

Report period

Q2 2026

Institutions

1

Top holders

1

REED full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 REED'S, INC. SEC filings REED'S, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of REED - REED'S, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Era Regenerative Medicine...
Disclosed value leader
Era Regenerative Medicine...
Comparable rows
15/15
Latest evidence
20 May 2026
13D/G 3/4/5 13F Lead comparable stake: 58% 13D/G row: Era Regenerative Medicine Ltd Showing 1-6 of 15 holder rows.

Quick read

Era Regenerative Medicine Ltd leads the comparable SEC ownership view at 58%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Era Regenerative Medicine Ltd's linked filing trail.
Comparable ownership Top 5
Era Regenerative Medicine Ltd 58%
Shufen Deng 54%
WHITEBOX ADVISORS LLC 0.8%
Neal Cohane 0%
ARMISTICE CAPITAL, LLC 4.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Era Regenerative Medicine Ltd
13D/G 3/4/5
10%+ Owner
13D/G 3/4/5
58%
$53,043,803
28,214,789 shares
 +$2,021,506 04 Jun 2025
Shufen Deng
13D/G 3/4/5
DENG, SHUFEN · Director
13D/G 3/4/5
54%
$15,907,672
6,363,069 shares
 $0 20 May 2026
WHITEBOX ADVISORS LLC
13D/G
13D/G
0.8%
$484,557
257,743 shares
 $0 31 Dec 2024
Neal Cohane
3/4/5
Chief Operating Officer
3/4/5
0%
$675
675 shares
 — 05 Jan 2026
ARMISTICE CAPITAL, LLC
13F
Company
13F
4.6%
$1,992,852
548,995 shares
 — 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
0.69%
$298,484
82,227 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
1
Shares
3
Rows available
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
17
Q2 2026 holders
1
Holder diff
-16
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .